Alnylam announced July 22 that its intellectual property estate has been strengthened due to the U.S. Patent Office's issuance of a Notice of Allowance for claims in one of its patent applications that covers "chemically modified RNA therapeutics conjugated with an N-acetylgalactosamine (GalNAc) ligand independent of length, sequence, or disease target," according to a statement.
Thanks to a recent court ruling, a former Celgene sales rep's off-label marketing lawsuit will go forward.
Thanks to a recent court ruling, a former Celgene sales rep's off-label marketing lawsuit will go forward. The rep, Beverly Brown, claims the company pushed its multiple myeloma drugs Thalomid and Revlimid for uses not approved by the FDA--and a judge says she's produced enough evidence to justify a trial.
Eagle Pharmaceuticals ($EGRX) has nabbed an FDA approval for its new-and-improved formulation of dantrolene sodium, which will be sold as Ryanodex, for potentially lethal cases of malignant hyperthermia.
A year after the FDA rejected Titan Pharmaceutical's Probuphine subdermal implant for the treatment of opioid dependence, the company is knocking on the approval door once again. It announced July 21 that the first patients have enrolled in its Phase III trial designed to address the FDA's questions.
The FDA is trying to regulate mobile medical apps lightly, but will have a hard time doing so as they become more sophisticated. Consider a future of mobile blood pressure and blood glucose monitors.
St. Jude Medical is hoping to strengthen its franchise in ablation catheters--thin, flexible wires inserted non-surgically into the heart to treat cardiac arrhythmia. Its FlexAbility irrigated ablation catheter has garnered a CE Mark in Europe, where it has marketed the TactiCath contact-force sensing irrigated ablation catheter since 2012. The company hopes to get FDA approval by year end for both FlexAbility and TactiCath.
Last week, it was priority review for cervical cancer. This week, it's the fast track for difficult-to-treat ovarian cancer.
Last week, it was priority review for cervical cancer. This week, it's the fast track for difficult-to-treat ovarian cancer. That's the record for Roche's Avastin, which is now up for quick FDA approval of two new indications.
The FDA has zoomed in on testosterone products for the cardiovascular risks they might pose to consumers, even slapping a new warning on their official labels. Now, the agency has called a special advisory committee meeting to probe two trials that flagged an increased risk of heart attack in men using the meds.